Integra LifeSciences Holdings Corporation $IART Shares Sold by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management S.A. sold 605,765 shares of Integra LifeSciences, reducing its stake by 33.7%, and now owns approximately 1.54% of the company's shares valued at $14.65 million.
• In contrast, several hedge funds increased their positions in Integra LifeSciences, with ProShare Advisors LLC raising their holdings by 44.5% in the fourth quarter.
• Integra LifeSciences reported $0.45 earnings per share for the last quarter, exceeding estimates, but revenue decreased 0.6% year-over-year, prompting future EPS guidance of 2.190-2.290 for FY 2025.

Assenagon Asset Management S.A. reduced its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 33.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,194,179 shares of the life sciences company's stock after selling 605,765 shares during the period. Assenagon Asset Management S.A. owned approximately 1.54% of Integra LifeSciences worth $14,653,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Integra LifeSciences by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock valued at $872,000 after purchasing an additional 1,437 shares in the last quarter. ProShare Advisors LLC raised its holdings in Integra LifeSciences by 44.5% in the fourth quarter. ProShare Advisors LLC now owns 20,361 shares of the life sciences company's stock valued at $462,000 after acquiring an additional 6,266 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Integra LifeSciences by 16.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 198,642 shares of the life sciences company's stock valued at $4,505,000 after acquiring an additional 28,457 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Integra LifeSciences in the fourth quarter valued at approximately $1,721,000. Finally, GAMMA Investing LLC raised its holdings in shares of Integra LifeSciences by 3,595.1% in the 1st quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company's stock valued at $5,140,000 after purchasing an additional 22,721 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Price Performance

Shares of IART opened at $14.41 on Tuesday. Integra LifeSciences Holdings Corporation has a twelve month low of $11.06 and a twelve month high of $27.13. The company has a current ratio of 1.23, a quick ratio of 0.73 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -2.21 and a beta of 1.20. The firm's fifty day simple moving average is $13.85 and its 200-day simple moving average is $15.11.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The business had revenue of $415.61 million for the quarter, compared to analyst estimates of $395.06 million. During the same quarter last year, the company earned $0.63 EPS. The business's quarterly revenue was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Equities analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.